About Ripharma
Ripharma is a Healthcare company based in India. Pharmaceutical discovery, development, and delivery in India. Its Indian entity Ripharma Laboratories Limited reported revenue of ₹68.14 Cr. Ripharma offers products and services including Yolovit and Bioeffer. Its focus areas include Pharmaceuticals, Drug Development, Formulations Manufacturing and Biotechnology.
Company details
Ripharma is recognized as a leading bio-pharmaceutical company in India, having been established in 2005 by professionals committed to fostering good health. The companys operations are known to encompass the full pharmaceutical value chain, including discovery, development, and delivery of innovative formulations. Manufacturing is conducted in units that are accredited with WHO-GMP, ensuring quality is prioritized. Relationships with renowned companies have been built, supporting a strong presence in domestic and international markets, where over 500 products are exported to more than 10 countries. Global alliances are encouraged to provide safer therapies.
- Headquarters India
- SectorsHealthcare
- Email••••••••
- Website ripharma.in
- Legal Name Ripharma Laboratories Ltd
- Date of Incorporation 25 Mar, 2015
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹68.14 Cr
FY 2025 · +146% YoY
- Net Profit₹6.03 Cr
FY 2025 · 9% margin
- EBITDA₹58.87 Cr
FY 2025 · 86% margin
Associated legal entities of Ripharma
Ripharma operates through Ripharma Laboratories Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Ripharma Laboratories Limited CIN U24100MH2015PLC262970 | Active | 25 Mar 2015 | Mumbai, Maharashtra | ₹68.1 Cr | 6 | View details |
Products & Services of Ripharma
Ripharma offers a comprehensive portfolio of products and services, including Yolovit and Bioeffer.
This product is developed as part of innovative health formulations
This formulation is provided within the company's range of advanced pharmaceutical offerings
Board of directors of Ripharma Laboratories Limited (Ripharma)
Ripharma Laboratories Limited is the primary company behind Ripharma. The board of Ripharma Laboratories Limited currently have 6 directors; the longest-serving is Rishabh Shreepal Jain, appointed in 2015. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rishabh Shreepal Jain DIN 06976344 | Director | 25 Mar 2015 | 11 yrs 7 mo | Ripharma Laboratories Limited |
| Shreepal Champalal Jain DIN 00457749 | Director | 25 Mar 2015 | 11 yrs 7 mo | Ripharma Laboratories Limited |
| Shrenik Champalal Jain DIN 00457755 | Director | 25 Mar 2015 | 11 yrs 7 mo | Ripharma Laboratories Limited |
| Milan Champalal Jain DIN 06388938 | Director | 25 Mar 2015 | 11 yrs 7 mo | Ripharma Laboratories Limited |
| Amit Shantilal Jain DIN 06864989 | Director | 25 Mar 2015 | 11 yrs 7 mo | Ripharma Laboratories Limited |
| Shantilal Rajmal Jain DIN 00457742 | Director | 04 Feb 2025 | 1 yr 9 mo | Ripharma Laboratories Limited |
Financials of Ripharma
Figures of Ripharma Laboratories Limited, the primary company behind Ripharma, for FY 2025. Revenue was ₹68.14 Cr (+146% year on year). Net profit was ₹6.03 Cr (9% margin). EBITDA was ₹58.87 Cr (86% margin).
- ₹68.14 CrRevenue · FY 2025 · +146% YoY
- ₹6.03 CrNet profit · 9% margin
- ₹58.87 CrEBITDA · 86% margin
- ₹5 LakhPaid-up capital
Balance sheet, profit and loss, cash flow and ratios of Ripharma Laboratories Limited are on its company page.
Detailed financial statements for Ripharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Ripharma
Ripharma is headquartered in India.
The primary company behind Ripharma, Ripharma Laboratories Limited, reported revenue of ₹68.14 Cr for FY 2025, up 146% year on year.
Ripharma is recognized as a leading bio-pharmaceutical company in India, having been established in 2005 by professionals committed to fostering good health. The companys operations are known to encompass the full pharmaceutical value chain, including discovery, development, and delivery of innovative formulations. Manufacturing is conducted in units that are accredited with WHO-GMP, ensuring quality is prioritized. Relationships with renowned companies have been built, supporting a strong presence in domestic and international markets, where over 500 products are exported to more than 10 countries. Global alliances are encouraged to provide safer therapies.
Ripharma offers Yolovit and Bioeffer.
Ripharma operates through Ripharma Laboratories Limited.
The legal entities of Ripharma currently have 6 directors, including Rishabh Shreepal Jain, Shantilal Rajmal Jain, Shreepal Champalal Jain and others.